Orthofix Medical Inc. (OFIX): Price and Financial Metrics

Orthofix Medical Inc. (OFIX): $24.29

0.75 (+3.19%)

POWR Rating

Component Grades














  • Value is the dimension where OFIX ranks best; there it ranks ahead of 90.04% of US stocks.
  • The strongest trend for OFIX is in Growth, which has been heading up over the past 179 days.
  • OFIX ranks lowest in Momentum; there it ranks in the 19th percentile.

OFIX Stock Summary

  • OFIX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2.62 -- higher than just 14.95% of US-listed equities with positive expected earnings growth.
  • The ratio of debt to operating expenses for Orthofix Medical Inc is higher than it is for about merely 11.24% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Orthofix Medical Inc is reporting a growth rate of -651.21%; that's higher than merely 3.31% of US stocks.
  • Stocks that are quantitatively similar to OFIX, based on their financial statements, market capitalization, and price volatility, are LPTH, SSD, LIQT, PNR, and MYO.
  • Visit OFIX's SEC page to see the company's official filings. To visit the company's web site, go to www.orthofix.com.

OFIX Valuation Summary

  • OFIX's EV/EBIT ratio is 67; this is 128.67% higher than that of the median Healthcare stock.
  • Over the past 243 months, OFIX's EV/EBIT ratio has gone up 61.8.
  • Over the past 243 months, OFIX's EV/EBIT ratio has gone up 61.8.

Below are key valuation metrics over time for OFIX.

Stock Date P/S P/B P/E EV/EBIT
OFIX 2021-08-31 1.8 2.3 -102.8 67.0
OFIX 2021-08-30 1.8 2.3 -101.1 65.8
OFIX 2021-08-27 1.8 2.3 -101.6 66.1
OFIX 2021-08-26 1.8 2.2 -99.0 64.3
OFIX 2021-08-25 1.8 2.2 -99.5 64.7
OFIX 2021-08-24 1.8 2.2 -99.9 65.0

OFIX Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -126.19%.
  • Its year over year net cashflow from operations growth rate is now at 41.09%.
  • The 3 year cash and equivalents growth rate now stands at 23.5%.
Over the past 15 months, OFIX's revenue has gone up $54,042,000.

The table below shows OFIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 464.479 18.475 -38.379
2021-09-30 457.034 28.987 -14.945
2021-06-30 455.591 44.442 -8.12
2021-03-31 407.332 64.249 -28.964
2020-12-31 406.562 74.272 2.517
2020-09-30 410.437 63.924 23.581

OFIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OFIX has a Quality Grade of B, ranking ahead of 90.59% of graded US stocks.
  • OFIX's asset turnover comes in at 0.885 -- ranking 26th of 186 Medical Equipment stocks.
  • LMAT, SRTS, and GMED are the stocks whose asset turnover ratios are most correlated with OFIX.

The table below shows OFIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.885 0.761 0.055
2021-03-31 0.757 0.744 -0.041
2020-12-31 0.763 0.749 0.009
2020-09-30 0.781 0.759 0.003
2020-06-30 0.802 0.764 -0.125
2020-03-31 0.933 0.780 -0.066

OFIX Price Target

For more insight on analysts targets of OFIX, see our OFIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $54.38 Average Broker Recommendation 1.4 (Strong Buy)

OFIX Stock Price Chart Interactive Chart >

Price chart for OFIX

OFIX Price/Volume Stats

Current price $24.29 52-week high $43.30
Prev. close $23.54 52-week low $23.17
Day low $23.35 Volume 82,500
Day high $24.38 Avg. volume 102,609
50-day MA $27.48 Dividend yield N/A
200-day MA $31.81 Market Cap 483.66M

Orthofix Medical Inc. (OFIX) Company Bio

Orthofix International provides reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The company was founded in 1987 and is based in Willemstad, Curaçao.

OFIX Latest News Stream

Event/Time News Detail
Loading, please wait...

OFIX Latest Social Stream

Loading social stream, please wait...

View Full OFIX Social Stream

Latest OFIX News From Around the Web

Below are the latest news stories about Orthofix Medical Inc that investors may wish to consider to help them evaluate OFIX as an investment opportunity.

Orthofix Non-GAAP EPS of $0.27 beats by $0.10, revenue of $125.06M beats by $0.23M

Orthofix press release (NASDAQ:OFIX): Q4 Non-GAAP EPS of $0.27 beats by $0.10. Revenue of $125.06M (+6.3% Y/Y) beats by $0.23M. FY22 outlook: The company expects revenue to be in the range of $475M- S490M vs consensus of $489.03M; Adj. EPS expected to be $0.58-$0.73 vs consensus of $0.82  ...

Seeking Alpha | February 25, 2022

Orthofix (OFIX) Tops Q4 Earnings and Revenue Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 25, 2022

Orthofix Reports Fourth Quarter and Fiscal Year 2021 Results

LEWISVILLE, Texas, February 25, 2022--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. Net sales for the fourth quarter were $125.1 million, earnings (loss) per share ("EPS") was $(1.65) and adjusted EPS was $0.27. For fiscal year 2021, net sales were $464.5 million, EPS was $(1.95) and adjusted EPS was $0.86.

Yahoo | February 25, 2022

Orthofix Expands Synthetic Bone Growth Offerings with Full Market Launch of Opus BA – a Bioactive Solution for Spine Procedures

LEWISVILLE, Texas, February 22, 2022--Orthofix expands biologics portfolio with Opus BA, a synthetic bone graft solution for cervical and lumbar spine fusion procedures.

Yahoo | February 22, 2022

Orthofix Medical Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 25, 2022

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the fourth quarter and full year 2021 before market open on Friday, February 25, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Companys results at 8:30 a.m. ET the same day. Interested p

Business Wire | February 10, 2022

Read More 'OFIX' Stories Here

OFIX Price Returns

1-mo -12.59%
3-mo -26.48%
6-mo -24.96%
1-year -40.00%
3-year -53.14%
5-year -47.31%
YTD -21.87%
2021 -27.66%
2020 -6.93%
2019 -12.02%
2018 -4.04%
2017 51.19%

Continue Researching OFIX

Here are a few links from around the web to help you further your research on Orthofix Medical Inc's stock as an investment opportunity:

Orthofix Medical Inc (OFIX) Stock Price | Nasdaq
Orthofix Medical Inc (OFIX) Stock Quote, History and News - Yahoo Finance
Orthofix Medical Inc (OFIX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4705 seconds.